Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.57 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | KAT7 | O95251 | 1/20 | 0.40 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481225 | 0.87 | P2RX7 (0.46) | P2RX7KAT8CNR2CNR1CRHR1 | |
| SCHEMBL2182502 | 0.86 | P2RX7 (0.46) | P2RX7KAT8CNR2CNR1CRHR1 | |
| SCHEMBL4465194 | 0.85 | P2RX7 (0.44) | P2RX7KAT8CNR2CNR1CRHR1 | |
| SCHEMBL4481062 | 0.84 | P2RX7 (0.44) | P2RX7KAT8CNR2CNR1CRHR1 | |
| SCHEMBL4473523 | 0.84 | P2RX7 (0.43) | P2RX7CNR2CNR1CRHR1 | |
| SCHEMBL2180488 | 0.82 | P2RX7 (0.50) | P2RX7KAT8CNR2KAT5CRHR1 | |
| SCHEMBL4466199 | 0.82 | P2RX7 (0.42) | P2RX7CNR2SMN1; SMN2 | |
| SCHEMBL4471082 | 0.81 | P2RX7 (0.40) | P2RX7SMN1; SMN2HPGD | |
| SCHEMBL2182071 | 0.81 | P2RX7 (0.53) | P2RX7KAT8CNR2KAT5CRHR1 | |
| SCHEMBL4467451 | 0.80 | P2RX7 (0.58) | P2RX7CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1837330-B1 | Benzamide inhibitors of the P2X7 receptor | PFIZER PROD INC (US) | 2012-10-24 | — | — | EP | claimed |
| EP-1837330-A1 | Benzamide inhibitors of the P2X7 receptor | Pfizer Products Inc. (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | PFIZER INC. | 2007-06-21 | — | — | US | claimed |
| EP-1837330-B1 | Benzamide inhibitors of the P2X7 receptor | PFIZER PROD INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7553972-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1837330-A1 | Benzamide inhibitors of the P2X7 receptor | Pfizer Products Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | PFIZER INC. | 2007-06-21 | — | — | US | disclosed |
| US-7186742-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER INC (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1626962-B1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | PFIZER PROD INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050009900-A1 | Benzamide inhibitors of the P2X7 receptor | ZOETIS LLC | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885KAT8 3086/4885CNR2 117/4885 |
| US-20050009900-A1 | Benzamide inhibitors of the P2X7 receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885KAT8 3086/4885CNR2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.